Should you buy Summit Therapeutics stock now?
No, the technical signal for Summit Therapeutics is currently SELL. Summit Therapeutics trades at $13.65 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.466 with falling momentum (signal: -0.455); RSI is at 45.2 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $28.37 points to 107.8% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Summit Therapeutics stock?
The average analyst price target for Summit Therapeutics is $28.37. The current price is $13.65, which gives an upside of 107.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $25.53 and $31.21.
Is Summit Therapeutics a dividend stock?
No, Summit Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Summit Therapeutics stock?
Summit Therapeutics is rated as a stock with extreme risk. the annual standard deviation is 73.4%, which classifies the stock as extreme risk.
Is Summit Therapeutics overvalued?
No, Summit Therapeutics is considered undervalued based on the analyst price target (107.8% upside). Summit Therapeutics has the following valuation ratios: a P/S ratio of 3,891.3, a P/B ratio of 16.5. The analyst price target suggests that the stock is undervalued by 107.8%.
Is Summit Therapeutics overbought?
No, Summit Therapeutics is not overbought. RSI is at 45.2 (neutral zone). The technical indicators show: RSI is at 45.2 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 2.8% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Summit Therapeutics earnings report?
Summit Therapeutics reports its next earnings on October 19, 2026. The stock currently trades at $13.65.
Is Summit Therapeutics shorted?
Yes, Summit Therapeutics is shorted with 24.6% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Summit Therapeutics stock?
Yes, insiders are net buyers of Summit Therapeutics – they are buying more shares than they are selling. Over the last 3 months, insiders have made 5 purchases and 0 sales. On a net basis, 103,255,150 $ worth of shares were bought. Across the last 20 reported transactions, the split is 20 purchases and 0 sales, with a net 410,799,635 $ bought. Active buyers include Zanganeh Mahkam, DUGGAN ROBERT W, Soni Manmeet Singh and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Summit Therapeutics a good stock?
Based on our total score, Summit Therapeutics is rated as a disastrous stock with a total score of 6 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 3/100, Quality: 4/100, Momentum: 12/100. In addition: analysts see 107.8% upside to the price target; technical signal: Strong Sell. Whether Summit Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Summit Therapeutics stock?
The outlook for Summit Therapeutics based on current data: the average analyst price target is $28.37 (+107.8%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 10/19/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Summit Therapeutics stock falling?
Summit Therapeutics is falling right now. The technical indicators show: the price is 2.8% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 24.6% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Summit Therapeutics go?
The average analyst price target for Summit Therapeutics is $28.37, which corresponds to a potential gain of 107.8% from the current price of $13.65. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Summit Therapeutics fall?
We lack enough history to give a specific floor for Summit Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Summit Therapeutics do?
Summit Therapeutics Inc. er et biofarmaceutisk firma, der primært udvikler kræftbehandlinger i USA og Storbritannien. De satser også på at lave nye præcisionsantibiotika, som skal bekæmpe infektioner, der er resistente over for medicin. For eksempel har de SMT-738, som er et a... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Summit Therapeutics as an investment.
Did Summit Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Summit Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Summit Therapeutics making money or losing money?
We have no current profitability data for Summit Therapeutics. See the latest report in the earnings history above.
Can Summit Therapeutics go bankrupt?
The bankruptcy risk of Summit Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -7.06 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 12% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Summit Therapeutics have a lot of debt?
No, Summit Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 12%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
